For young Indians grappling with aortic valve disease, the Ross procedure offers a lifeline—one that restores vitality ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

Transcatheter Aortic Valve Replacement Market outlook through 2035, highlighting key trends, growth drivers, challenges, and future opportunities ...

The “passive” notification led to more patients with severe AS undergoing valve replacement, but more can be done still.

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

With traditional valve replacements often tied to a lifetime of medication and limitations, Dr Varun Shetty, Consultant – ...

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...

Edwards Lifesciences (NYSE: EW) today announced eight-year data highlighting positive long-term outcomes with its proprietary ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...

The Heart Valve Devices Market is valued at USD 12.18 Billion in 2024 and is expected to reach USD 41.88 Billion by 2035 at a ...